null

null

null

null

null

null

null

null

null

null

null

null

null

null

5.91x Total Debt / Equity (High leverage)

High sensitivity; Inotiv carries ~$300M+ debt post-Envigo acquisition; 200bps rate rise adds ~$6M annual interest expense, pressuring already thin EBITDA margins

Medium intensity; US-China trade tariffs on metals and components disrupt supply chains.

Live animal procurement (India/China rodent colonies) and specialty feed/bedding sourcing concentrated in few approved vendors create dual geopolitical chokepoints

Moderate exposure; UK (GBP), EU (EUR), and Canada (CAD) represent top international markets; GBP/EUR devaluation vs USD compresses reported revenue ~5-8%

Operations in US, UK, EU, Canada, Israel; GBP, EUR, CAD devaluation risk estimated at 5-10% revenue impact; no significant emerging-market currency exposure

Medium intensity; commodities: Steel, Aluminum, Copper, Crude Oil (fuel), Rare Earth Elements, Plastics/Resins; geopolitical: US-China trade tariffs on metals and components disrupt supply chains.

Envigo-legacy animal supply network and Charles River-competitive supplier relationships; no single vendor exceeds 30% but colony health vendors are near-non-substitutable short-term

Primarily lab services and CRO (contract research organization); minimal cloud-native infrastructure dependency; AWS termination would disrupt data systems but not core wet-lab operations

Secondary discovery services and drug metabolism software (ADMET Predictor); cloud termination would critically disrupt software delivery for ~15-20% of revenue segment

Moderate API coupling risk; ADMET Predictor software has proprietary API integrations; pharma clients face moderate switching costs due to validated workflows and regulatory audit trails

Low Howey Test risk; revenue derived from fee-for-service CRO contracts and software licenses; not a passive investment scheme; Howey inapplicable

Medium

Moderate GDPR/CCPA exposure; handles preclinical trial data across EU jurisdictions; UK post-Brexit data transfer rules add compliance layer; no major enforcement actions noted

Moderate; Envigo acquisition raised DOJ scrutiny of rodent model supply concentration; ongoing monitoring likely; market share in research model supply warrants continued regulatory attention

Medium burden; regimes: FAA, DOT, OSHA, EPA, ITAR, FTC; Export controls and defense procurement rules create contract concentration risk.

Approximately 60-70% recurring via multi-year CRO service contracts and software subscriptions; 30-40% transactional project-based study fees

Primarily fee-for-service study execution and recurring software license (ADMET Predictor SaaS); secondary through research model sales (animals and biologics)

Cost-plus pricing dominates CRO services; vulnerable to labor/feed inflation pass-through delays; software segment has stronger margin architecture but small revenue base

Low-to-moderate; CRO market is competitive with Charles River, Labcorp, Covance; limited ability to raise prices without client attrition; software segment has higher pricing power

5.9% Gross Margin (Thin (<20%))

Low free-rider risk; services are paid and proprietary; moderate churn risk from pharma client budget cuts; repeat study business is high but not contractually locked long-term

Highly headcount-linear; animal care, lab technicians, and study directors scale directly with study volume; doubling revenue requires near-doubling of skilled labor headcount

High marginal cost; capacity expansion requires facility capex plus headcount; software segment (ADMET) is sublinear but represents minority of revenue; overall model is not scalable

Not a franchise model; null

At 10x scale, CAC economics worsen due to limited pharma/biotech universe; unit economics marginally improve on software but deteriorate on services due to facility and labor constraints

Weak network effects; ADMET Predictor has modest data-network benefit as more users improve model training; CRO services have no meaningful network effect

-11.4% Return on Assets (Negative equity)

Moderate recession resistance; preclinical CRO demand tied to pharma R&D budgets which are semi-resilient but biotech client segment is highly sensitive to funding environment

Large pharmaceutical and biotechnology companies representing majority of CRO service revenue; top 10 clients likely represent 40-50% of revenue creating concentration risk

Academic institutions and government agencies (NIH-funded research) purchasing research models and discovery services; lower revenue concentration but more price-sensitive

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "17-0000 Architecture and Engineering Occupations", "23-0000 Legal Occupations", "33-0000 Protective Service Occupations", "37-0000 Building and Grounds Cleaning and Maintenance Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "47-0000 Construction and Extraction Occupations", "49-0000 Installation, Maintenance, and Repair Occupations", "51-0000 Production Occupations", "53-0000 Transportation and Material Moving Occupations"]

0.3 (HIL — ~30% of characteristic roles agent-automatable)

Capital is being defensively deployed to remediate Envigo facility compliance issues (USDA/AAALAC violations) rather than growth infrastructure; legacy liability capex dominates FY2023-2024

0000720154

NOTV